一种生物型人工肝支持系统治疗急性肝功能衰竭犬的效应

Effects of a hollow fiber bioartificial liver system to treat acute liver failure canines

  • 摘要: 目的:评价我们改进的生物型人工肝系统(BALS)治疗急性肝功能衰竭犬的有效性和安全性。方法:在引进中空纤维管式BALS基本技术的基础上,将中国实验用小型猪肝细胞培养于BALS中,对醋氨酚诱发ALF模型犬进行透析治疗,测定治疗前、后肝衰犬血液GPT、NH3、GOP、BUN及AKP等生化指标及肝脏组织学的变化。结果:采用此种BALS对ALF犬治疗4~6h,其血氨、GPT、GOT和AKP等生化指标均明显降低(P<0.01);而药物组和对照组其治疗前、后这些生化指标均无明显改变(P>0.05)。药物组和对照组的肝衰犬均在治疗后6~36h内死亡,而透析组的肝衰犬在治疗后可长期存活(大于30d)。BALS治疗效果明显优于常规的药物治疗(P<0.01)。结论:此种BALS能迅速、安全、有效地纠正药物诱发性ALF犬的肝脏功能

     

    Abstract: Objective:To evaluate the safety and efficacy of the hollow fiber bioartificial liver system in canines with acute liver failure.Methods:9 canines with acute liver failure by Acetaminaphen received TECA-I bioartificaial liver system (BALS)from Hong kong TECA Limited, blood was perfused through a hollow fiber tube containing (1~3)×1010 the porcine hepatocytes. 10 canines with acute liver failure by Acetaminaphen received drugs. Each treatment lasted 6 hours. Results:BALS treatment resulted in beneficial effects with decreased plasma ammonia (from 135.9±17.5 to 65.7±22, 32.5±8.8 umol/L), GPT(from 97.8±8.7 to 64.8±11.9,19.0±6.3 U/L), GOT (from 103.0±16.7 to 75.7±19.6,26.5±5.0 U/L) and AKP (from 158.3±12.1 to 114.5±19.8,43.8±5.6 U/L) which lasted for the duration of the treatment and 30 days thereafter. In contrast, 10 canines with acute liver failure in the drug group wre death after treatment 1~2 days. Conclusion:This bioartificaial liver system is safe and efficacious in canines with acute liver failure.

     

/

返回文章
返回